Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone

Diabetic Medicine

Volumn 26, Issue 6, 2009, Pages 577-581

  Park, S E ^b   Kang, E S ^a   Kim, D H ^c   Kim, S K ^d   Lee, J H ^b   Ahn, C W ^a   Lee, H C ^a   Cha, B S ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d CHA University   (South Korea)

Author keywords

Atherogenic dyslipidaemia; ATP binding cassette transporter 1; Genetic association; Rosiglitazone

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; CHOLESTEROL BILE LEVEL; CONTROLLED STUDY; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN VARIANT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 66449117634     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02728.x     Document Type: Article

References (22)

1. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An anti-diabetic thiazolidinedione is a high-affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR-γ). J Biol Chem 1995 270 : 12953 12956.
2. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996 45 : 1661 1669. (Pubitemid 26398943)
3. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 28 : 1547 1554. (Pubitemid 40923063)
4. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004 164 : 2097 2104. (Pubitemid 39419498)
5. Shim WS, Do MY, Kim SK, Kim HJ, Hur KY, Kang ES et al. The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol (Oxf) 2006 65 : 453 459. (Pubitemid 44414268)
6. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007 30 : 2458 2464. (Pubitemid 47547772)
7. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999 100 : 1134 1146. (Pubitemid 29416243)
8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 339 : 229 234. (Pubitemid 28350165)
9. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001 42 : 1173 1179. (Pubitemid 32744239)
10. Daimon M, Kido T, Baba M, Oizumi T, Jimbu Y, Kameda W et al. Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population. Biochem Biophys Res Commun 2005 329 : 205 210. (Pubitemid 40255441)
11. Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, Villalobos-Comparan M, Rodriguez-Cruz M, Miliar-Garcia A et al. Association of the ATP-binding cassette transporter A1 R230C variant with early onset Type 2 diabetes in the Mexican population. Diabetes 2007 56 : 1881 1887.
12. Pasdar A, Yadegarfar G, Cumming A, Whalley L, St Clair D, MacLeod MJ. The effect of ABCA1 gene polymorphisms on ischaemic stroke risk and relationship with lipid profile. BMC Med Genet 2007 8 : 30.
13. Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001 103 : 1198 1205. (Pubitemid 32221340)
14. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001 7 : 53 58. (Pubitemid 32095642)
15. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB et al. A PPAR-γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001 7 : 161 171. (Pubitemid 32162909)
16. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007 13 : 340 347. (Pubitemid 46376682)
17. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma [FER(HDL)]. Clin Biochem 2001 34 : 583 588. (Pubitemid 34014853)
18. Dobiasova M, Stribrna J, Sparks DL, Pritchard PH, Frohlich JJ. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb 1991 11 : 64 70.
19. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988 260 : 1917 1921. (Pubitemid 18230558)
20. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 2003 14 : 593 600. (Pubitemid 36246002)
21. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008 40 : 1092 1097.
22. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008 40 : 1098 1102.